Skip to content
CDC

Antimicrobial Resistance

Linezolid-resistant MRSA

% Resistant in 2024

0.0% Resistant

Number of Resistant Isolates of the Total Number of Isolates Tested In 2024

1 Resistant

/ 2,626 Tested

% Resistant by Patient Age in 2024

Pediatric:
0.0% Resistant
Adult:
0.0% Resistant

Pathogen Profile

Linezolid-resistant MRSA

Staphylococcus aureus causes a range of illnesses, from skin and wound infections to pneumonia and bloodstream infections that can lead to sepsis and death. These data represent the proportion of all methicillin-resistant S. aureus (MRSA) that are also resistant to linezolid, limiting treatment options for such infections.

Current Threat Report

Threat LevelSerious

Estimated Cases323,700

Estimated Deaths10,600

Healthcare Costs (USD)$1.7 B

Source: COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2024

Years Included
2011 - 2024
Resources

Geographic Locations

Antimicrobial resistance varies by location, driven by a number of factors, including antibiotic use and infection control practices in individual healthcare facilities, the underlying health and age of the patient population, and regional spread from nearby locations.

Percent Linezolid resistance Among Staphylococcus aureus by State Map

This map shows the variation in % linezolid resistance among Staphylococcus aureus causing all event types in 2024.

Percent Linezolid resistance Among Staphylococcus aureus by State

Percent Linezolid resistance Among by State
Locationvalue
Alabama0
AlaskaInsufficient Data
Arizona0
Arkansas0
California0
Colorado0
ConnecticutInsufficient Data
DelawareInsufficient Data
District of ColumbiaInsufficient Data
Florida0
Georgia0
HawaiiInsufficient Data
IdahoInsufficient Data
Illinois0
Indiana0
IowaInsufficient Data
KansasInsufficient Data
Kentucky0
Louisiana0
MaineInsufficient Data
Maryland0
Massachusetts0
Michigan0
Minnesota0
Mississippi0
Missouri0
MontanaInsufficient Data
NebraskaInsufficient Data
Nevada0
New HampshireInsufficient Data
New Jersey0
New MexicoInsufficient Data
New York0
North Carolina0
North DakotaInsufficient Data
Ohio0
Oklahoma0
Oregon0
Pennsylvania0
Puerto RicoInsufficient Data
Rhode IslandInsufficient Data
South Carolina0
South DakotaInsufficient Data
Tennessee0
Texas0
UtahInsufficient Data
VermontInsufficient Data
Virginia0
Washington0
West Virginia0
Wisconsin0
WyomingInsufficient Data

Percent Linezolid resistance Among Staphylococcus aureus by State List

Geography

Geography
statevalue
United States0.0%
Alabama0.0%
AlaskaNo Data
Arizona0.0%
Arkansas0.0%
California0.0%
Colorado0.0%
ConnecticutNo Data
DelawareNo Data
District of ColumbiaNo Data

Changes Over Time in Linezolid resistance Among Staphylococcus aureus

This graph displays percent antimicrobial resistance from 2011 to 2024 for all event types. Blank areas of the chart represent 0% resistance, indicating that zero resistant pathogens were reported for the selected year, phenotype, and HAI type. “Insufficient data” indicates that less than 20 pathogens were isolated and tested for resistance.

Changes Over Time in Linezolid resistance Among Staphylococcus aureus
Year% Resistant
20110.8
20120.7
20130.8
20140.7
20150.6
20160.5
20170.9
20180.5
20190.3
20200.4
20210.4
20220.4
20230.3
20240

Healthcare Facility Type

The setting or type of healthcare facility can influence the types of procedures and prevention measures that are related to healthcare-associated infections and antimicrobial resistance.

Linezolid resistance Among Staphylococcus aureus by Hospital Type

This graph displays percent antimicrobial resistance by hospital type in 2024.

Percent resistant Among Staphylococcus aureus by Hospital Type

Percent resistant Among Staphylococcus aureus by Hospital Type
Hospital Type% Resistant
General Acute Care Hospitals0
Long Term Acute Care Hospitals0

Footnotes

  • HAIs include Catheter-associated Urinary Tract Infections (CAUTI), Central Line-associated Bloodstream Infections (CLABSI), and Surgical Site Infections (SSI).
  • CI (Confidence Interval) - The national, regional, and state-level data included in Antimicrobial Resistance information are displayed with 95% confidence intervals around the percent resistance, which were calculated using a mid-P exact test and are an indication of precision.
  • Map legends are classified using the Jenks Natural Breaks method.